White House Accelerates Mental Health Innovation and Psychedelic Treatments

Definium Therapeutics applauds executive order to expand access to emerging psychedelic therapies

Apr. 18, 2026 at 11:38pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray image of a human brain, with glowing neural pathways and synaptic connections, conceptually representing the potential of psychedelic medicines to unlock new pathways for mental health treatment.Emerging psychedelic therapies aim to address the persistent unmet needs in mental health by targeting the brain's complex neural networks.NYC Today

Definium Therapeutics, a late-stage biopharmaceutical company, has issued a statement supporting a new White House executive order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medical treatments. The order directs federal agencies to prioritize mental health therapies, streamline regulatory pathways, and expand collaboration to increase access to psychedelic medicines.

Why it matters

The executive order represents a significant shift in federal policy, recognizing the potential of psychedelic medicines to address the persistent unmet treatment needs for mental health disorders. This could pave the way for faster development and approval of new therapies, providing hope for millions of Americans suffering from conditions like generalized anxiety disorder and major depressive disorder.

The details

Definium Therapeutics is advancing a clinical development program for its proprietary DT120 (lysergide tartrate) orally disintegrating tablet, an ergoline derivative that acts as a partial agonist at serotonin receptors. The company believes DT120 ODT could offer advantages like faster absorption, improved bioavailability, and fewer gastrointestinal side effects compared to other psychedelic treatments.

  • The White House executive order was signed on April 18, 2026.
  • Definium Therapeutics is currently in late-stage clinical trials for DT120 ODT.

The players

Definium Therapeutics

A late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders.

Rob Barrow

Chief Executive Officer of Definium Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Accelerating scientific progress depends on both rigor and urgency, and we thank the Administration and welcome this Executive Order as an important recognition of the persistent unmet treatment needs in serious mental illness.”

— Rob Barrow, Chief Executive Officer

“We applaud the Administration's recognition that psychedelic medicines may represent meaningful new treatment options for patients. We are advancing a comprehensive clinical development program for DT120 (lysergide tartrate) for millions of patients living with conditions including generalized anxiety disorder (GAD) and major depressive disorder (MDD).”

— Rob Barrow, Chief Executive Officer

What’s next

Definium Therapeutics plans to continue advancing its clinical development program for DT120 ODT, with the goal of seeking regulatory approval for the treatment of generalized anxiety disorder and major depressive disorder.

The takeaway

The White House executive order represents a significant shift in federal policy, recognizing the potential of psychedelic medicines to address the persistent unmet treatment needs for mental health disorders. This could accelerate the development and approval of new therapies, providing hope for millions of Americans suffering from conditions like anxiety and depression.